Quality of life and patient preference for sequential versus continuous combined HRT: The UK Kliofem ® multicenter study experience

International Journal of Gynecology and Obstetrics

Volumn 59, Issue SUPPL. 1, 1997, Pages

  Ulrich, L G ^a   Barlow, D H ^b   Sturdee, D W ^c   Wells, M ^d   Campbell, M J ^e   Nielsen, B ^f   Bragg, A J ^g   Vessey, M P ^h  

^a John Radcliffe Hospital ^*  (Denmark)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c SOLIHULL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e NORTHERN GENERAL HOSPITAL   (United Kingdom)

^f Novo Nordisk ^*  (Denmark)

^g Novo Nordisk Ltd   (United Kingdom)

^h RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Compliance; Hormone replacement therapy; Kliogest; Patient preference; Sequential versus continuous combined therapy

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADIOL VALERATE PLUS NORGESTREL; KLIOFEM; MESTRANOL PLUS NORETHISTERONE; PREMPAK; TRISEQUENS; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CLIMACTERIUM; CLINICAL TRIAL; DRUG PREFERENCE; DRUG PROGRAM; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATIENT ATTITUDE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; UNITED KINGDOM;

EID: 0030867983     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0020-7292(97)90194-6     Document Type: Article

References (21)

1. Kiel DP, Felson DP, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogen in postmenopausal women; the Framingham Study. N Engl J Med 1987;317:1169-1174.
2. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;10:821-828.
3. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.
4. Tuppurainen M, Kroger H, Honkanen R, Puntila E, Huopio J, Saarikoski S et al. Risks of perimenopausal fractures - a prospective population-based study. Acta Obstet Gynecol Scand 1995;74:624-628.
5. Spector TD, Brennan P, Harris PA, Studd JW, Silman AJ. Do current regimes of hormone replacement therapy protect against subsequent fractures? Osteoporos Int 1992;2:219-224.
6. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.
7. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.
8. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336:1769-1775.
9. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-1334.
10. Hahn RG. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161:1854-1855.
11. Coope J, Marsh J. Can we improve compliance with long-term HRT. Maturitas 1992;15:151-158.
12. Barentsen R, Groenveld FPMJ, Bareman FP, Hoes AW, Dokter HJ, Drogendijk AC. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993;51:203-207.
13. Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy: a survey of women's knowledge and attitudes. Arch Intern Med 1989;149:133-136.
14. Schneider HPG. Which data exist: state-of-the-art. In: Birkhäuser MH, Rozenbaum H, editors. Menopause: European Consensus Development Conference, Montreux, Switzerland. Paris: Editions ESKA, 1996:193-205.
15. Grady D, Gebretsadik J, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
16. Rees M. On menstrual bleeding with hormone replacement therapy. Lancet 1994;343:250.
17. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3:145-156.
18. Dören M, Reuther G, Minne HW, Schneider HPG. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995;173:1446-1451.
19. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996;19(Suppl. 5):191S-193S.
20. Sturdee DW, Barlow DH, Ulrich LG, Wells M, Campbell M, Vessey MP et al. for the UK Continuous Combined HRT Study Investigators. Prevalence of endometrial hyperplasia with sequential oestrogen-progestogen replacement therapy (in preparation).
21. Wells M, Sturdee DW, Barlow DH, Ulrich LG, Campbell M, Vessey MP et al. for the UK Continuous Combined HRT Study Investigators. Endometrial response to continuous combined HRT (in preparation)